Mirador Capital Partners LP Sells 8,541 Shares of Astera Labs, Inc. $ALAB

Mirador Capital Partners LP trimmed its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 48.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,242 shares of the company’s stock after selling 8,541 shares during the quarter. Mirador Capital Partners LP’s holdings in Astera Labs were worth $1,810,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ALAB. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Astera Labs during the second quarter worth $29,000. Bernard Wealth Management Corp. bought a new stake in shares of Astera Labs in the second quarter valued at about $36,000. Clearstead Trust LLC grew its holdings in shares of Astera Labs by 46,100.0% in the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after acquiring an additional 461 shares in the last quarter. Advisors Asset Management Inc. grew its position in shares of Astera Labs by 68.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after acquiring an additional 194 shares during the period. Finally, Manchester Capital Management LLC lifted its holdings in Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after purchasing an additional 283 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Trading Up 0.9%

ALAB stock opened at $144.94 on Wednesday. The firm has a 50 day moving average of $163.73 and a 200-day moving average of $154.73. The firm has a market capitalization of $24.48 billion, a P/E ratio of 130.58, a price-to-earnings-growth ratio of 2.68 and a beta of 1.51. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.39 by $0.10. The firm had revenue of $230.58 million during the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The business’s quarterly revenue was up 103.9% compared to the same quarter last year. During the same period last year, the firm earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Sell-side analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insiders Place Their Bets

In other Astera Labs news, CEO Jitendra Mohan sold 90,459 shares of Astera Labs stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the completion of the sale, the chief executive officer directly owned 2,080,418 shares in the company, valued at $301,015,680.42. The trade was a 4.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Sanjay Gajendra sold 90,459 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the completion of the transaction, the chief operating officer directly owned 1,599,750 shares in the company, valued at $231,467,827.50. The trade was a 5.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 586,936 shares of company stock worth $89,331,140. 12.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ALAB has been the topic of a number of recent research reports. Northland Capmk upgraded Astera Labs from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 17th. Wall Street Zen downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Barclays reiterated an “equal weight” rating and issued a $155.00 price target on shares of Astera Labs in a report on Monday, October 20th. Morgan Stanley reissued an “overweight” rating and issued a $210.00 price objective on shares of Astera Labs in a research note on Wednesday, December 3rd. Finally, TD Cowen cut their target price on Astera Labs from $225.00 to $170.00 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $188.17.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.